Niraparib 100mg Capsules

Niraparib 100mg Capsules is a highly potent, oral Poly (ADP-ribose) Polymerase (PARP) inhibitor designed to target and exploit specific genetic vulnerabilities in cancer cells. As a targeted therapy, Niraparib 100mg Capsules functions through a mechanism known as “synthetic lethality.” In normal cells, PARP enzymes are responsible for repairing single-strand DNA breaks. When Niraparib inhibits these enzymes, these single-strand breaks accumulate and evolve into double-strand breaks during DNA replication. In cancer cells that already have defects in their Homologous Recombination Repair (HRR) pathway—such as those with BRCA1 or BRCA2 mutations—the cell cannot repair these double-strand breaks effectively. This inability to repair DNA damage leads to genomic instability and ultimately triggers apoptosis (cell death). Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for extending remission in ovarian cancer, offering a powerful maintenance therapy that works even in patients without germline BRCA mutations.

The development of Niraparib 100mg Capsules has revolutionized the maintenance treatment landscape. Unlike some earlier therapies restricted solely to patients with specific genetic mutations, Niraparib 100mg Capsules has demonstrated efficacy in a broader population, including those with Homologous Recombination Deficiency (HRD) positive status and even those with proficient DNA repair mechanisms, although the benefit is most pronounced in the former. The 100mg capsule strength allows for flexible, individualized dosing (typically starting at 200mg or 300mg daily) based on the patient’s body weight and platelet count, a strategy that significantly improves tolerability.

Indications / Uses of Niraparib 100mg Capsules

Niraparib 100mg Capsules is commonly prescribed for the specialized management of gynecologic cancers:

• First-Line Maintenance Treatment: It is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
• Recurrent Ovarian Cancer Maintenance: The medication is used for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
• Homologous Recombination Deficiency (HRD) Positive Tumors: While effective broadly, it is a primary choice for patients whose tumors test positive for HRD (defined by either a deleterious BRCA mutation or genomic instability), where it provides the most substantial extension of progression-free survival.

Key Features

• Broad Efficacy Profile: The primary feature of Niraparib 100mg Capsules is its ability to provide clinical benefit to patients regardless of their BRCA mutation status, unlike some earlier PARP inhibitors.
• Convenient Once-Daily Dosing: The medication is taken orally once a day, with or without food, preferably at bedtime to manage potential nausea, offering a simple regimen for long-term maintenance.
• High Bioavailability: Niraparib 100mg Capsules demonstrates excellent absorption and tissue distribution, capable of crossing the blood-brain barrier in preclinical models.
• Customizable Dosing: The availability of the 100mg unit allows oncologists to tailor the starting dose (e.g., 200mg for patients <77kg or with lower platelets) to minimize adverse events without compromising efficacy.
• Progression-Free Survival Extension: Clinical trials have consistently shown that maintenance therapy with Niraparib significantly delays the return of cancer compared to placebo.

Storage for Niraparib 100mg Capsules

To preserve the pharmacological stability and ultimate potency of the active ingredients, Niraparib 100mg Capsules should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F to 86°F). It is vital to keep the capsules in their original bottle or blister packaging to protect them from light and environmental moisture. Do not transfer the medication to generic pill boxes unless they are airtight. For maximum safety, always store Niraparib 100mg Capsules in a secure, high location that is strictly out of the reach and sight of children and pets.

Important Note on Niraparib 100mg Capsules

The administration of Niraparib 100mg Capsules requires vigilant monitoring of hematologic parameters. Myelosuppression (decreased bone marrow activity) is a common and potentially serious side effect. Thrombocytopenia (low platelet count), anemia (low red blood cells), and neutropenia (low white blood cells) occur frequently, particularly in the first few months of treatment. Complete blood counts (CBC) should be monitored weekly for the first month, monthly for the next 11 months, and periodically thereafter. Dose interruptions or reductions are often necessary if blood counts drop significantly.

Hypertension (high blood pressure) and hypertensive crisis have been reported. Blood pressure and heart rate should be monitored at least weekly for the first two months, then monthly for the first year. Hypertension should be managed with antihypertensive medication; if uncontrolled, Niraparib may need to be paused. There is also a risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), a secondary bone marrow cancer, occurring in patients exposed to PARP inhibitors; if confirmed, the drug must be discontinued. Common side effects include nausea, fatigue, and constipation. Taking the dose at bedtime can help mitigate nausea. Niraparib 100mg Capsules can cause fetal harm; effective contraception is mandatory for women of reproductive potential during treatment and for 6 months after the final dose. By strictly following these professional guidelines and attending regular blood pressure and lab checks, patients can safely maximize the remission-extending benefits of Niraparib 100mg Capsules.